Rydex Health Care Fund Class Investor RYHIX

Medalist Rating as of | See Rydex Investment Hub
  • NAV / 1-Day Return 149.66  /  +0.24 %
  • Total Assets 20.1M
  • Adj. Expense Ratio
    1.390%
  • Expense Ratio 1.380%
  • Distribution Fee Level Above Average
  • Share Class Type No Load
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield 0.00
  • Turnover 244%

USD | NAV as of Jul 10, 2026 | 1-Day Return as of Jul 10, 2026, 12:11 AM GMT+0

Morningstar’s Analysis RYHIX

Will RYHIX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Rydex Health Care Inv holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYHIX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 24.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

4.16 855,649
Healthcare

Johnson & Johnson

3.37 693,567
Healthcare

AbbVie Inc

2.78 573,359
Healthcare

Merck & Co Inc

2.43 499,744
Healthcare

Thermo Fisher Scientific Inc

2.06 423,543
Healthcare

UnitedHealth Group Inc

2.04 419,492
Healthcare

Gilead Sciences Inc

1.97 405,125
Healthcare

Amgen Inc

1.96 404,444
Healthcare

Abbott Laboratories

1.79 369,215
Healthcare

Intuitive Surgical Inc

1.79 369,089
Healthcare

Sponsor Center